Cortisone acetate
As of the edition of 20 October 2026, Cortisone acetate is a small molecule: marketed, first approved in 1973 (CA); acts on NR3C1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Cortone
- First approved
- 31 December 1973 (CA)
- Approvals on record
- 11 in 2 regions
- Holder of the most recent approval
- Merck & Co.; 5 holders in all
- Registered trials
- 2, 0 stopped early
- Disease areas
- Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Cortisone acetate.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NR3C1 | Glucocorticoid receptor | P04150 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bausch Health | Acquired holder | 1973 to now |
| Panray Corp Sub Ormont Drug And Chemical | Acquired holder | 2003 to now |
| Amneal Pharmaceuticals | Later holder | |
| Merck & Co. | Applicant | |
| Pfizer | Later holder |